Supreme Court May Be Next After Federal Circuit Refuses To Rehear Teva Inhaler Patents Case

 
• By Urtė Fultinavičiūtė

Teva was forced to delist its ProAir HFA inhaler patents from the FDA’s Orange Book by mid-March after the Federal Circuit denied its petition for en banc rehearing. Will the Supreme Court listen?

Photo of the US Supreme Court
If the appeals court decision stands, companies could decide to voluntarily delist some patents from the Orange Book. (Shutterstock)

More from Generics

More from Patents